Original language | English (US) |
---|---|
Pages (from-to) | 30-34 |
Number of pages | 5 |
Journal | International Journal of Radiation Oncology Biology Physics |
Volume | 112 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2022 |
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: International Journal of Radiation Oncology Biology Physics, Vol. 112, No. 1, 01.01.2022, p. 30-34.
Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Back to the Future
T2 - Charting the Direction of Lower Grade Glioma Trials With Lessons From the Present and Past
AU - Kim, Michelle M.
AU - Hattangadi-Gluth, Jona A.
AU - Redmond, Kristin J.
AU - Trifiletti, Daniel M.
AU - Soltys, Scott G.
AU - Milano, Michael T.
N1 - Funding Information: Disclosures: M.M.K. reports research funding from BlueEarth Diagnostics. K.J.R. reports research funding from Elekta AB, Accuray, and Cannon; payment/honoraria from NCCN and Accuray; payment for expert testimony from the University of Michigan; support to attend meetings/travel from Brainlab, Accuray, and Elekta AB; and participation on the advisory board for BioMimetix. D.M.T. reports research funding from BlueEarth Diagnostics, Novocure, and Varian Medical Systems and consulting fees from Boston Scientific Corp. S.G.S. reports research funding from Novocure and payment/honoraria from Zap Surgical, Inc. M.T.M. reports royalties from UptoDate, consulting feeds from Galera Therapeutics, and payment/honoraria from AstraZeneca. Funding Information: Disclosures: M.M.K. reports research funding from BlueEarth Diagnostics. K.J.R. reports research funding from Elekta AB, Accuray, and Cannon; payment/honoraria from NCCN and Accuray; payment for expert testimony from the University of Michigan; support to attend meetings/travel from Brainlab, Accuray, and Elekta AB; and participation on the advisory board for BioMimetix. D.M.T. reports research funding from BlueEarth Diagnostics, Novocure, and Varian Medical Systems and consulting fees from Boston Scientific Corp. S.G.S. reports research funding from Novocure and payment/honoraria from Zap Surgical, Inc. M.T.M. reports royalties from UptoDate, consulting feeds from Galera Therapeutics, and payment/honoraria from AstraZeneca.
PY - 2022/1/1
Y1 - 2022/1/1
UR - http://www.scopus.com/inward/record.url?scp=85120807431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120807431&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2021.10.002
DO - 10.1016/j.ijrobp.2021.10.002
M3 - Editorial
C2 - 34919877
AN - SCOPUS:85120807431
SN - 0360-3016
VL - 112
SP - 30
EP - 34
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -